JHJennifer Scarlet Haas

Jennifer Scarlet Haas

*This is an algorithmically generated author record based on publicly available information.

Jennifer Scarlet Haas has a total of 59 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Understanding the economic and healthcare burden of metabolic dysfunction-associated steatohepatitis: a real-world claims data analysis from Germany

    by Frank Tacke, Yestle Kim, Jennifer S Haas, Melinda J Daumont, Christopher Maas, John O'DOnnell, Jörn M Schattenberg

    Aim: Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive form of metabolic dysfunction-associated steatotic liver disease, linked to hepatic and extra-hepatic complications and substantial healthcare costs. Despite its clinical and economic impact, real-world evidence on disease progression and costs in Germany is limited. Materials & methods: We conducted a retrospective cohort study using statutory health insurance claims from the InGef database (2016–2023), covering 4.7% of the German population. Patients with MASH were identified using ICD-10-GM code K75.8, in absence of the more specific code in the German coding system. Baseline characteristics and comorbidities were assessed over 2 years prior to index diagnosis. Progression was defined by transitions through end-stage liver disease (ESLD) stages: compensated cirrhosis, decompensated cirrhosis, hepatocellular carcinoma and liver transplantation. Healthcare costs were analyzed descriptively and via regression models. Results: Among 4710 patients with MASH (prevalence: 0.15%), 39.4% had documented ESLD during follow-up (mean follow-up in days 1530). Disease progression to ESLD occurred in 26.0% of patients without baseline ESLD (n = 922/3490), whereas 4.0% of patients with baseline ESLD (n = 48/1188) progressed to a more severe ESLD stage during follow-up, with a mean time to first progression of approximately 25.3 months. Patients with ESLD incurred annual costs of €12,737 versus €4928 for those without ESLD. Progression to hepatocellular carcinoma and liver transplantation resulted in predicted costs of €12,948 and €75,719 per patient-year, respectively. Mortality was significantly higher among patients with ESLD (incidence rate ratio: 4.65; 95% CI: 3.76–5.79). Discussion: Over a quarter of identified patients with MASH already had advanced liver disease at baseline, suggesting potential underdiagnosis or late recognition in routine clinical practice. Early detection, proactive management and targeted therapies are essential to reduce progression and economic burden.

  • Open Access

    Metabolic Dysfunction–Associated Steatohepatitis Diagnosis and Management in Germany: Insights From an Expert Consensus Panel

    by Yestle Kim, Peter Rydqvist, Thomas Ramezani, Jennifer S. Haas, Heike Bantel, Peter Buggisch, Andreas Geier, Wolf‐Peter Hofmann, Stefan Mauss, Elke Roeb, et al.

    Background: Metabolic dysfunction–associated steatotic liver disease (MASLD) is a major cause of chronic liver disease. Metabolic dysfunction‐associated steatohepatitis (MASH), a progressive form of MASLD, can lead to fibrosis and cirrhosis. The incidence and burden of MASH in Germany are expected to double by 2030, while diagnostic and management challenges persist. Expert consensus on diagnostic strategies and treatment modalities in MASLD and MASH is required.Objectives: The panel aimed to gather insights and consensus on the diagnostic pathway and current treatment modalities for MASH in Germany.Methods: A three‐round web‐based survey, integrating Delphi panel methodology with a standard survey, was conducted from February to May 2024 to reach consensus on predefined questions. The survey involved 12 gastroenterology, diabetology and/or hepatology specialists in Germany.Results: The Delphi panel revealed that ~75% of MASH patients in Germany remain undiagnosed. Non‐invasive measures, such as fibrosis scores (values from clinical and imaging tests to assess fibrosis), liver enzyme tests and liver stiffness measurement, were primary methods for diagnosing and monitoring MASH patients. Lifestyle modifications were the primary management strategy, given the absence of approved pharmacological treatments for MASH. The panel also highlighted significant challenges in managing MASH, including the lack of approved medications and the difficulty in sustaining lifestyle changes.Conclusions: The survey underscores the substantial underdiagnosis of MASH and the reliance on non‐invasive diagnostic methods in Germany. The lack of approved treatments necessitates a focus on lifestyle modifications and comorbidity management. The Delphi panel's insights call for enhanced screening, early detection and standardised algorithms to improve patient outcomes.


  • Open Access

    The impact of anti-inflammatory therapy on Parkinson's disease incidence: A retrospective cohort study

    by Michele Potashman, Jennifer S. Haas, Ambrish Pandit, Dana Stafkey, Vlad Coric, Wolfgang Singer, Gil L'ITalien


  • Open Access

    Safety and Persistence of Nalmefene Treatment for Alcohol Dependence. Results from Two Post-authorisation Safety Studies

    by Jonathan Chick, Frank Andersohn, Sylvie Guillo, Kathrin Borchert, Massoud Toussi, Sebastian Braun, Jennifer S Haas, Kavitha Kuppan, Ole M Lemming, Elin Heldbo Reines, et al.

    Two post-authorisation studies assessed the safety and persistence of patients’ use of nalmefene. The START study (EUPAS5678) was a non-interventional, multi-country, prospective, 18-month (8 follow-up visits) cohort study including outpatients initiating nalmefene for the first time. The multi-database retrospective cohort study (MDRC, EUPAS14083) included baseline and follow-up data from German, Swedish and UK healthcare databases. Both studies permitted ‘all comers’ without explicit exclusion criteria; predefined subgroups of interest included the elderly (≥65 years) as well as patients with significant psychiatric and/or somatic comorbidities. START study: Overall, the mean duration of nalmefene treatment was 10.3 ± 7.3 months (N = 1348), with 49.0% of patients treated for ≥1 year; frequent reasons for treatment discontinuation were ‘goal reached’ and ‘drug cost’. The most frequently reported adverse drug reactions (ADRs) were nausea (4.7%), dizziness (3.2%) and insomnia (2.0%). ADR rates appeared higher in the elderly subpopulation (18.6% reported ≥1 ADR vs. 12.0% in the total population) but were not higher in the other predefined subgroups. MDRC study: The database follow-up analysis followed 2892 patients over 18 months for whom the duration of nalmefene treatment was between 2 and 3 months and <5% of patients used nalmefene for ≥1 year. Despite the inclusion of a wider patient population (e.g. elderly patients and those with relevant co-morbidities), the safety and tolerability profile of nalmefene given in routine practice was consistent with previous clinical studies. The differing rates of persistence beyond 1 year likely reflect the different methodologies and highlight the relevance of psychosocial support at follow-up visits.


  • Open Access

    Patterns and predictors of mortality and disease progression among patients with non‐alcoholic fatty liver disease

    by Ali Canbay, Nandita Kachru, Jennifer Scarlet Haas, Jan‐Peter Sowa, Dominic Meise, Ahmet Burak Ozbay

    Summary: Background: Factors associated with mortality and disease progression in non‐alcoholic fatty liver disease (NAFLD) and non‐alcoholic steatohepatitis (NASH) are poorly understood.Aims: To assess the impact of liver disease severity, demographics and comorbidities on all‐cause mortality and liver disease progression in a large, real‐world cohort of NAFLD patients.Methods: Claims data from the German Institut für angewandte Gesundheitsforschung database between 2011 and 2016 were analyzed retrospectively. Adult patients diagnosed with NAFLD and/or NASH were categorised as NAFLD, NAFLD non‐progressors, compensated cirrhosis, decompensated cirrhosis, liver transplant or hepatocellular carcinoma (HCC). The longitudinal probability of mortality and incidence of progression were calculated for disease severity cohorts and multivariable analyses performed for adjusted mortality.Results: Among 4 580 434 patients in the database, prevalence of NAFLD was 4.7% (n = 215 655). Of those, 36.8% were non‐progressors, 0.2% compensated cirrhosis, 9.6% decompensated cirrhosis, 0.0005% liver transplant and 0.2% HCC. Comorbidity rates were significantly higher in compensated cirrhosis, decompensated cirrhosis and HCC compared with non‐progressors. The longitudinal probability of mortality for non‐progressors, compensated cirrhosis, decompensated cirrhosis and HCC was 3.6%, 18.7%, 28.8% and 68%, respectively. Independent predictors of mortality included cardiovascular disease, type 2 diabetes mellitus, hypertension, obesity and renal impairment. The cumulative incidence of progression in NAFLD and compensated cirrhosis patients was 10.7% and 16.7%, respectively, over 5 years of follow‐up.Conclusion: NAFLD patients were severely under‐diagnosed and had a high probability of mortality that increased with disease progression. Early identification and effective management to halt or reverse fibrosis are essential to prevent progression.


  • Open Access

    The burden of hyperkalemia in Germany – a real world evidence study assessing the treatment and costs of hyperkalemia

    by Jennifer Scarlet Haas, Kim-Sarah Krinke, Christopher Maas, Thomas Hardt, Isabella Barck, Sebastian Braun

    Background: Hyperkalemia (HK) can affect health outcomes and quality of life, as it is referred to as a potentially life-threatening condition caused by an increased serum potassium concentration in the blood. Patients suffering from heart failure or chronic kidney diseases are at a higher risk of HK, which can further be amplified by the treatment received. To date, data on HK prevalence is lacking for Germany and the aims of this study were to assess HK and compare health-relevant outcomes and healthcare costs between HK patients and non-HK patients. Methods: The InGef research database containing healthcare claims of over 4 million individuals in Germany was utilized for this retrospective, matched cohort analysis. Patients with non-acute outpatient treated and a subgroup of patients with chronic HK, were identified in 2015 with an individual 1 year pre- and post-index period, taking the first observable HK diagnosis/treatment in 2015 into account as the index event. To identify non-acute outpatient treated HK patients, at least two ICD-10-GM diagnosis codes E87.5 “Hyperkalemia” and/or prescriptions of polystyrene sulfonate were required. Chronic HK patients had additional diagnoses and/or prescriptions in all quarters following the first observable HK diagnosis. Patients without HK were matched 1:1 to the respective HK cohorts. Results: In the year 2015, 3333 patients with non-acute outpatient treated HK were identified of which 1693 were patients with chronic HK. After matching, 3191 and 1664 HK patients and controls were available for analysis. A significantly higher number of hospitalizations was observed for both HK cohorts in comparison to their matched controls. Dialysis initiation as well as the healthcare costs were higher for both HK cohorts when compared to their matched counterparts. Conclusions: The disease burden was higher for patients with HK, based on a higher proportion of patients with dialysis initiation and higher healthcare costs.


  • Open Access

    Healthcare resource use and costs of multiple sclerosis patients in Germany before and during fampridine treatment

    by Tjalf Ziemssen, Christine Prosser, Jennifer Scarlet Haas, Andrew Lee, Sebastian Braun, Pamela Landsman-Blumberg, Angela Kempel, Erika Gleißner, Sarita Patel, Ming-Yi Huang

    Multiple sclerosis (MS) patients often suffer from gait impairment and fampridine is indicated to medically improve walking ability in this population. Patient characteristics, healthcare resource use, and costs of MS patients on fampridine treatment for 12 months in Germany were analyzed. A retrospective claims database analysis was conducted including MS patients who initiated fampridine treatment (index date) between July 2011 and December 2013. Continuous insurance enrollment during 12 months pre- and post-index date was required, as was at least 1 additional fampridine prescription in the fourth quarter after the index date. Patient characteristics were evaluated and pre- vs post-index MS-related healthcare utilization and costs were compared. A total of 562 patients were included in this study. The mean (standard deviation [SD]) age was 50.5 (9.8) years and 63% were female. In the treatment period, almost every patient had at least 1 MS-related outpatient visit, 24% were hospitalized due to MS, and 79% utilized MS-specific physical therapy in addition to the fampridine treatment. Total MS-related healthcare costs were significantly higher in the fampridine treatment period than in the period prior to fampridine initiation (€17,392 vs €10,960, P < 0.001). While this difference was driven primarily by prescription costs, MS-related inpatient costs were lower during fampridine treatment (€1,333 vs €1,565, P < 0.001). Physical therapy is mainly used concomitant to fampridine treatment. While healthcare costs were higher during fampridine treatment compared to the pre-treatment period, inpatient costs were lower. Further research is necessary to better understand the fampridine influence.


  • Open Access

    Assessing asthma severity based on claims data: a systematic review

    by Christian Jacob, Jennifer S. Haas, Benno Bechtel, Peter Kardos, Sebastian Braun

    Asthma is one of the most common chronic diseases in Germany. Substantial economic evaluation of asthma cost requires knowledge of asthma severity, which is in general not part of claims data. Algorithms need to be defined to use this data source.


  • Open Access

    Burden of influenza in Germany: a retrospective claims database analysis for the influenza season 2012/2013

    by Jennifer Haas, Sebastian Braun, Peter Wutzler

    Objective Seasonal influenza occurs in annual epidemics. The virus can cause severe illness and concomitant diseases with the highest risk for children, the elderly, and individuals with disease dispositions. The study objective is to assess the influenza burden in Germany. Methods This retrospective claims data analysis used the Health Risk Institute research database containing anonymized data of 4 million individuals. The study period comprised the influenza season 2012/2013 in which patients with documented influenza were identified. Disease frequency rates were calculated for a population with disease dispositions and a population not at high risk. Disease burden was assessed based on health-services utilization during the influenza season. Vaccine rates were calculated by identifying vaccinations. Results We observed 65,826 patients with influenza, resulting in 1,160,646 documented influenza cases after extrapolation. Overall, otitis media and pneumonia was higher in the influenza-infected population compared to the non-influenza-infected population and especially high in children. Hospitalization cost amounted to €87,202,485 with a mean stay of 7 days, and total outpatient costs were €14,947,976. Vaccination rates were 60. Conclusions Seasonal influenza can cause severe outcomes with hospitalizations and excess costs. Especially influenza-infected children are affected by concomitant diseases with higher disease burden. Furthermore, documented vaccination rates are quite low.